Novel Cholesterol Therapy Flops And Company Ends Development

–13 years after ApoA-1 Milano sparked excitement the novel HDL therapy appears to be dead. After 13 years and despite the efforts of 3 separate companies, the novel cholesterol therapy known as ApoA-1 Milano appears to be dead. On Monday afternoon the Medicines Company announced that it had discontinued development of the drug and would...Click here to continue reading...

Source: CardioBrief - November 8, 2016 Category: Cardiology Authors: Larry Husten Tags: People, Places & Events Prevention, Epidemiology & Outcomes apo-A-1 Esperion HDL Medicines Company Pfizer Source Type: blogs